FDA Will Release Follow-On Biologics Background Document By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The document will illustrate prior regulatory treatment paths for natural source-derived and biotech protein products, so it should not cause any controversy, Acting Commissioner for Operations Woodcock says.